Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug-delivery platforms, recently announced further advances in
its proprietary, oral, drug-delivery platform: DehydraTECH(TM). An article
discussing the company reads, “Lexaria’s early pilot-stage human trials with
tetrahydrocannabinol (THC) delivery show its newest formulation of
DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less
than 10 minutes, which is about twice as fast as traditional DehydraTECH and four
to six times faster than generic industry formulations, according to a company
news release (http://ibn.fm/mwAS9).
. . . Lexaria has been developing DehydraTECH solutions as alternatives to
smoked or vaped drug delivery over the course of the past three years,
establishing a means whereby edible consumption of certain substances can
provide results at rates comparable to inhaled substances and faster than
ingested substances in general.”
To view the full article, visit http://ibn.fm/hAOOi
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment